Introduction

Rybelsus, Novo Nordisk's oral semaglutide product, has become an important reference point in the development of GLP-1 therapies. Introduced as a once-daily tablet for adults with type 2 diabetes, it addressed one of the longstanding limitations of peptide-based medicines: delivering a GLP-1 receptor agonist orally rather than by injection.

The product's position is changing again. In 2025, the U.S. Food and Drug Administration (FDA) expanded the Rybelsus label to include reduction of major adverse cardiovascular events in adults with type 2 diabetes at high cardiovascular risk. European regulators also incorporated cardiovascular-outcome evidence into the European Rybelsus label. At the same time, Novo Nordisk has developed a newer oral semaglutide formulation and shifted its U.S. oral diabetes branding from Rybelsus to Ozempic tablets.

This transition makes Rybelsus particularly relevant to pharmaceutical market analysis. The molecule itself remains semaglutide, but the commercial proposition is being reshaped through formulation improvements, branding, cardiovascular evidence, and the expansion of oral semaglutide into obesity treatment.

The change is already visible in Novo Nordisk's financial results. Rybelsus generated DKK 22.1 billion in sales in 2025, but sales declined 5% in Danish kroner compared with 2024. Novo Nordisk attributed part of the pressure to reprioritization toward other GLP-1 treatments. The company continues to commercialize Rybelsus internationally while building a broader semaglutide portfolio that includes injectable Ozempic and Wegovy as well as the newer Wegovy pill.

For the healthcare industry, Rybelsus therefore represents more than another diabetes medicine. It provides a case study in oral peptide delivery, lifecycle management, cardiometabolic drug development, manufacturing strategy, reimbursement, and the increasingly competitive GLP-1 market.

What Is Rybelsus?

Rybelsus contains semaglutide, a long-acting glucagon-like peptide-1 receptor agonist, or GLP-1 RA. Semaglutide mimics the activity of the naturally occurring GLP-1 hormone and activates GLP-1 receptors involved in glucose regulation and appetite-related signaling.

Its glucose-lowering effects include glucose-dependent stimulation of insulin secretion and suppression of glucagon secretion. Semaglutide also slows gastric emptying, particularly during the early postprandial period, and can influence appetite and food intake.

The defining feature of Rybelsus is its oral formulation. Peptide medicines are generally vulnerable to degradation in the gastrointestinal tract and have poor absorption when taken by mouth. Novo Nordisk addressed this problem by incorporating salcaprozate sodium, commonly referred to as SNAC, an absorption-enhancing excipient. The technology facilitates absorption of semaglutide, with absorption occurring predominantly in the stomach.

This formulation requires specific administration conditions. Current U.S. labeling instructs patients to take the tablet once daily on an empty stomach with a limited amount of plain water and wait at least 30 minutes before eating, drinking other beverages, or taking other oral medicines. These requirements are not incidental; they are directly related to the pharmacokinetic characteristics of oral semaglutide.

Regulatory status

Rybelsus received U.S. approval in 2019 for improving glycemic control in adults with type 2 diabetes as an adjunct to diet and exercise. The European Union granted marketing authorization in April 2020 for adults with insufficiently controlled type 2 diabetes, including use as monotherapy when metformin is inappropriate and in combination with other diabetes medicines.

The U.S. regulatory position changed materially in October 2025. FDA approved Rybelsus to reduce the risk of major adverse cardiovascular events cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke in adults with type 2 diabetes who are at high risk for these events. 

A further development occurred in 2026. FDA approved the proprietary name Ozempic for newer 1.5 mg, 4 mg, and 9 mg oral semaglutide tablets. The formulation provides bioavailability comparable to the original 3 mg, 7 mg, and 14 mg Rybelsus formulations. Novo Nordisk began making the newer Ozempic tablets available in the United States in May 2026.

This means that the Rybelsus brand and oral semaglutide technology should not be treated as the same commercial entity in every market. Rybelsus remains the relevant product name in many international markets, including the European Union, while the United States is moving toward an Ozempic-branded oral semaglutide offering.

Recent Developments and Trends

SOUL strengthens the cardiovascular evidence base

The most important clinical development for Rybelsus is the SOUL cardiovascular outcomes trial.

The trial enrolled 9,650 adults with type 2 diabetes and established atherosclerotic cardiovascular disease, chronic kidney disease, or both. Participants were randomized to oral semaglutide or placebo in addition to standard care and were followed for a mean of approximately 47.5 months.

A major adverse cardiovascular event occurred in 12.0% of participants receiving oral semaglutide compared with 13.8% receiving placebo. The hazard ratio was 0.86, with a 95% confidence interval of 0.77 to 0.96.

These findings provided the evidence supporting the 2025 U.S. label expansion.

The commercial importance is substantial because diabetes treatment increasingly extends beyond HbA1c reduction. Cardiovascular outcomes can influence clinical guidelines, payer assessments, treatment sequencing, and the perceived value of a therapy.

SOUL also differentiates oral semaglutide from many older oral diabetes medicines for which cardiovascular evidence is less central to commercial positioning.

European cardiovascular label expansion

The cardiovascular evidence also influenced the European regulatory position. In September 2025, Novo Nordisk announced that the European Medicines Agency's Committee for Medicinal Products for Human Use had approved an update to the Rybelsus label reflecting cardiovascular benefits demonstrated in SOUL.

This development strengthens the role of Rybelsus within the European diabetes market, although the exact reimbursement and prescribing consequences continue to depend on national health systems.

For pharmaceutical companies, the European experience also demonstrates why regulatory approval and market access are separate steps. A label expansion creates clinical positioning opportunities, but national reimbursement bodies and healthcare systems ultimately determine how quickly those opportunities translate into utilization.

Higher-dose oral semaglutide research

The PIONEER PLUS phase 3b trial examined higher oral semaglutide doses of 25 mg and 50 mg compared with the approved 14 mg formulation in adults with inadequately controlled type 2 diabetes.

At week 52, mean HbA1c reductions were 1.5 percentage points with 14 mg, 1.8 percentage points with 25 mg, and 2.0 percentage points with 50 mg. The higher doses also produced greater reductions in body weight.

Gastrointestinal adverse events were more common with the higher-dose formulations, although most were described as mild to moderate.

PIONEER PLUS matters strategically because it demonstrated that oral semaglutide could be developed beyond the original Rybelsus dose range. That evidence became part of a broader formulation and indication strategy rather than remaining an isolated diabetes-development program.

New formulation creates both opportunity and implementation risk

Rybelsus has undergone a formulation transition designed to improve oral semaglutide bioavailability. The European Medicines Agency issued a direct healthcare professional communication in 2025 warning about medication-error risks associated with introduction of the new formulation.

The newer formulation uses different tablet strengths while providing comparable therapeutic exposure to the older formulation at corresponding doses. The U.S. labeling likewise emphasizes that the different oral formulations are not interchangeable on a milligram-for-milligram basis.

For manufacturers, formulation upgrades can extend the commercial lifecycle of an established active ingredient. For pharmacies and healthcare systems, they introduce a different operational requirement: ensuring that prescribing, dispensing, inventory, and patient communication remain synchronized.

Rybelsus transitions toward a broader oral semaglutide franchise

The U.S. introduction of Ozempic tablets in 2026 is one of the clearest signs that Novo Nordisk is treating oral semaglutide as part of a wider semaglutide platform.

The company stated that the new oral Ozempic formulation uses the same active semaglutide molecule but carries new branding and updated strengths. The stated purpose is to align oral and injectable diabetes products under the better-known Ozempic name.

This changes the commercial narrative around Rybelsus. Instead of simply defending a mature brand, Novo Nordisk can leverage recognition of semaglutide and the Ozempic brand while moving patients toward the newer oral formulation.

Impact on the Healthcare Industry

Oral delivery expands GLP-1 treatment options.

Rybelsus established oral delivery as a viable route for semaglutide. That has implications for the broader GLP-1 market because the route of administration is an important component of product differentiation.

Injectable GLP-1 medicines require device-based administration, whereas oral semaglutide eliminates injections but introduces strict administration requirements. Neither approach is universally more convenient; the relevant consideration depends on patient preferences, clinical circumstances, treatment routines, and healthcare-system infrastructure.

The commercial significance lies in choice. Oral delivery gives clinicians another way to incorporate a GLP-1 receptor agonist into diabetes management.

Cardiovascular evidence changes treatment value.

The SOUL findings strengthen the position of oral semaglutide in cardiometabolic care because they establish evidence for cardiovascular risk reduction in the population covered by the updated U.S. indication.

This can affect how physicians evaluate the product relative to diabetes therapies whose principal evidence base is glycemic control.

It can also influence health technology assessments. A medicine that potentially reduces cardiovascular events can be evaluated through a broader economic framework involving downstream healthcare utilization rather than acquisition cost alone.

Pharmaceutical R&D is moving toward cardiometabolic platforms

Rybelsus illustrates the movement from single-indication drug development toward platform-based cardiometabolic portfolios.

Novo Nordisk can use semaglutide across diabetes and obesity, with oral and injectable formulations addressing different segments. Other companies are pursuing their own GLP-1, GIP/GLP-1, glucagon, and multi-receptor strategies.

For research organizations, this creates a larger competitive-intelligence requirement. Monitoring individual products is no longer sufficient; companies must track molecules, formulations, indications, delivery technologies, cardiovascular outcomes, renal evidence, manufacturing capacity, and reimbursement simultaneously.

Manufacturing becomes a strategic consideration

Semaglutide is a peptide rather than a conventional small molecule, and oral delivery requires specialized formulation technology. Scaling production across multiple semaglutide products therefore involves more than simply increasing tablet output.

Novo Nordisk's broader investment in GLP-1 manufacturing capacity reflects the commercial importance of supply. As oral semaglutide expands into additional formulations and indications, production planning becomes closely connected to product launches and market access.

The resolved Rybelsus shortage previously recorded by EMA also illustrates how supply constraints can become part of the market analysis for established products.

Market and Business Implications

Rybelsus is now part of a multi-product semaglutide ecosystem

From a market-research perspective, evaluating Rybelsus independently of Ozempic and Wegovy can lead to an incomplete assessment.

The same active ingredient is now represented across multiple brands, routes, doses, and therapeutic indications. Ozempic is positioned around type 2 diabetes, Wegovy around obesity and related cardiovascular risk reduction, and oral semaglutide has increasingly diversified across cardiometabolic applications.

This creates portfolio synergies but also internal competition for manufacturing resources, promotional attention, and patient demand.

Novo Nordisk's 2025 sales data illustrates the distinction. Rybelsus remained a multibillion-kroner product, but sales declined as the company prioritized other GLP-1 therapies.

Oral obesity treatment changes the competitive equation

The arrival of oral semaglutide in obesity treatment is particularly important.

In late 2025, the FDA approved Wegovy tablets containing oral semaglutide for chronic weight management in eligible adults. The OASIS 4 trial provided phase 3 evidence supporting the higher-dose oral formulation in adults with overweight or obesity without diabetes.

This does not make Rybelsus an obesity medicine. Rybelsus and Wegovy have different approved indications and commercial positioning.

The development does, nevertheless, increase the strategic value of oral semaglutide technology. For Novo Nordisk, the ability to apply the same molecule through different formulations and brands creates opportunities to address multiple cardiometabolic segments.

Reimbursement will determine how much of the opportunity becomes demand

The GLP-1 category faces a major affordability and reimbursement question.

In the United States, CMS launched the Medicare GLP-1 Bridge on July 1, 2026. The temporary demonstration provides eligible Medicare Part D beneficiaries access to selected GLP-1 medicines used for weight management at a $50 monthly copay. The included products are Wegovy injection and tablets, Foundayo, and Zepbound KwikPen; Rybelsus is not one of the products listed for the weight-management demonstration.

Rybelsus can still be covered under applicable diabetes benefits and plan policies when used for its approved diabetes indications.

This distinction demonstrates why pharmaceutical market forecasts need indication-level analysis. A medicine's potential patient population is not the same as its reimbursed patient population.

Patent protection supports continued branded strategy

Novo Nordisk's 2025 annual report lists Rybelsus patent expiry dates of 2032 in the United States, 2026 in China, 2031 in Japan, and 2031 in Europe, while noting that patent status varies by country and that the table is based on specific patent categories and jurisdictions.

The timing matters because formulation, process, and other intellectual-property rights can influence the commercial lifecycle of a product even when the underlying active ingredient is well established.

For competitors, this creates a strategic incentive to monitor formulation patents and regulatory pathways rather than focusing only on the active molecule.

International markets remain important

Novo Nordisk reported that international operations supported Rybelsus sales in 2025 despite declining U.S. sales. 

International opportunities vary according to diabetes prevalence, healthcare spending, reimbursement, private-pay capacity, physician familiarity with GLP-1 medicines, and access to competing therapies.

Markets such as India are particularly relevant to the global diabetes pharmaceutical landscape because of the country's large diabetes population and established pharmaceutical manufacturing sector. Yet oral GLP-1 adoption depends on affordability and access as much as clinical interest.

For market-entry strategies, the relevant question is therefore not simply whether Rybelsus is approved in a country. It is whether the local healthcare system can support sustained use of a relatively high-value branded cardiometabolic therapy.

Key Companies and Industry Participants

Novo Nordisk

Novo Nordisk is the developer and commercial owner of Rybelsus and the wider semaglutide franchise. Its strategy now extends across oral and injectable diabetes treatments, obesity products, cardiovascular outcomes, and next-generation formulations.

The company's 2025 annual report reported DKK 22.093 billion in Rybelsus sales and DKK 152.202 billion in total GLP-1-based sales for type 2 diabetes. The difference illustrates how Rybelsus fits within a much larger portfolio.

U.S. Food and Drug Administration

FDA determines the U.S. regulatory framework for Rybelsus and approved the cardiovascular-risk-reduction indication in 2025. The agency also approved the newer Ozempic tablet proprietary name and formulation in 2026.

Its decisions directly influence prescribing information, commercial claims, market access, and lifecycle strategy.

European Medicines Agency

EMA granted Rybelsus an EU marketing authorization in 2020 and continues to oversee product information and post-marketing safety.

Its 2025 communication on formulation-related medication errors demonstrates the regulatory role involved when a commercially important medicine changes strength and formulation.

Clinical research institutions and investigators

The PIONEER program, PIONEER PLUS, PIONEER 6, and SOUL collectively established much of the evidence base for oral semaglutide.

These studies are important not only for regulatory purposes but also for market positioning because diabetes medicines are increasingly differentiated through cardiovascular, renal, weight, and safety outcomes.

Competing pharmaceutical companies

Eli Lilly is a major competitor through tirzepatide products Mounjaro and Zepbound, which target both GIP and GLP-1 pathways. Other companies are developing oral GLP-1 receptor agonists and multi-receptor therapies.

The competitive landscape is moving toward medicines that can combine glucose lowering, weight reduction, cardiometabolic outcomes, and convenient administration.

Challenges and Limitations

Rybelsus has several practical and commercial limitations.

The first is administration. Taking oral semaglutide under fasting conditions and separating it from food, beverages, and other oral medicines requires a level of routine adherence that differs from conventional tablets.

The second is gastrointestinal tolerability. Nausea, abdominal pain, diarrhea, decreased appetite, vomiting, and constipation are among the most common adverse reactions in current U.S. labeling. Gastrointestinal effects can influence treatment continuation and therefore have commercial implications for persistence.

The medicine also carries a boxed warning concerning thyroid C-cell tumors based on findings in rodents. Rybelsus is contraindicated in people with a personal or family history of medullary thyroid carcinoma or with Multiple Endocrine Neoplasia syndrome type 2.

Other labeled warnings include pancreatitis, diabetic retinopathy complications, hypoglycemia when used with insulin or insulin secretagogues, acute kidney injury associated with volume depletion, severe gastrointestinal adverse reactions, hypersensitivity, gallbladder disease, and pulmonary aspiration during general anesthesia or deep sedation.

Post-marketing safety surveillance has also expanded. In June 2025, EMA's Pharmacovigilance Risk Assessment Committee concluded that non-arteritic anterior ischemic optic neuropathy, or NAION, is a very rare adverse effect of semaglutide medicines, including Rybelsus. The committee recommended updating product information accordingly.

These developments demonstrate the importance of lifecycle pharmacovigilance for a high-profile medicine. Regulatory scrutiny does not necessarily eliminate commercial value, but it can influence prescribing behavior, risk communication, physician education, and patient selection.

Another limitation is competitive intensity. Rybelsus competes with injectable GLP-1 therapies, dual incretin medicines, SGLT2 inhibitors, insulin, and established oral diabetes drugs. The arrival of newer oral GLP-1 candidates may also reduce the uniqueness of oral delivery over time.

Finally, the U.S. transition from Rybelsus to Ozempic tablets creates a market-communication challenge. Pharmacies, prescribers, payers, and patients need clear information about the relationship between the original and newer formulations, especially because their strengths are not directly interchangeable on a milligram-for-milligram basis.

Future Outlook

Rybelsus is entering a different phase of its commercial lifecycle.

The cardiovascular indication gives oral semaglutide a broader evidence base in type 2 diabetes, while the development of higher-dose formulations creates opportunities for applications beyond the original Rybelsus proposition.

The U.S. transition to Ozempic tablets is likely to be particularly important for Novo Nordisk's brand strategy. Rather than treating Rybelsus as an isolated oral product, the company can position oral semaglutide within the established Ozempic franchise while retaining Rybelsus as an important international brand.

The expansion of oral semaglutide into obesity through Wegovy tablets also changes the strategic environment. It provides a direct demonstration that the oral delivery platform can support higher-dose cardiometabolic treatment, although the obesity product remains distinct from Rybelsus from a regulatory and commercial standpoint.

Future competition will likely focus on four areas: efficacy, route of administration, cardiometabolic outcomes, and affordability. Companies developing oral GLP-1 or multi-receptor therapies will seek to demonstrate that tablets can deliver competitive clinical outcomes without unacceptable tolerability or administration burdens.

Manufacturing capacity will remain relevant as well. The ability to supply multiple semaglutide formulations consistently may influence commercial execution just as strongly as clinical differentiation.

For healthcare market researchers, the most important indicators to monitor include oral GLP-1 launches, reimbursement changes, cardiovascular and renal outcomes, formulation transitions, patent developments, real-world persistence, manufacturing expansion, and competitive pricing.

Rybelsus therefore remains relevant even as the original U.S. brand identity changes. Its longer-term significance lies in the validation of oral peptide delivery and in the role it played in turning semaglutide from a single diabetes product into a broader cardiometabolic platform.

Conclusion

Rybelsus changed the competitive discussion around GLP-1 medicines by demonstrating that semaglutide could be delivered as a tablet rather than exclusively through injection. Its development combined peptide engineering with absorption-enhancing technology and created a differentiated option for type 2 diabetes treatment.

The product's clinical position has strengthened through the SOUL cardiovascular outcomes trial and the resulting 2025 U.S. and European label developments. At the same time, its commercial identity is changing. Novo Nordisk has introduced a newer oral semaglutide formulation under the Ozempic name in the United States and is extending oral semaglutide into obesity through Wegovy tablets.

That creates a nuanced outlook for Rybelsus itself. The original brand may become less central in the United States, while remaining important in other markets. The underlying technology, clinical evidence, and semaglutide franchise continue to expand.

For the healthcare industry, Rybelsus offers a useful example of how pharmaceutical value can evolve through formulation innovation, additional outcome evidence, regulatory lifecycle management, and portfolio strategy. Its market trajectory will depend not only on clinical efficacy, but also on reimbursement, manufacturing capacity, competition from newer incretin therapies, safety surveillance, and the ability of pharmaceutical companies to translate oral delivery into sustained real-world adoption.

Source References

• U.S. Food and Drug Administration (FDA) - Rybelsus Prescribing Information, 2025. 
• U.S. Food and Drug Administration - Rybelsus Supplemental New Drug Application Approval Letter, 2025. 
• U.S. Food and Drug Administration - Rybelsus and Ozempic Tablets Prescribing Information, revised January 2026. 
• U.S. Food and Drug Administration - Ozempic Tablets Supplemental New Drug Application Approval Letter, 2026. 
• DailyMed - Rybelsus and Ozempic Tablets: Prescribing Information, January 2026. 
• European Medicines Agency (EMA) - Rybelsus: European Public Assessment Report and Product Information, updated 2026. 
• European Medicines Agency - Rybelsus: Direct Healthcare Professional Communication on New Formulation and Medication-Error Risk, 2025. 
• European Medicines Agency - PRAC Concludes Eye Condition NAION Is a Very Rare Side Effect of Semaglutide Medicines, 2025. 
• McGuire DK, et al. - Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes. New England Journal of Medicine, 2025. 
• Husain M, et al. - Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. New England Journal of Medicine, 2019. 
• Aroda VR, et al. - Efficacy and Safety of Once-Daily Oral Semaglutide 25 mg and 50 mg Compared with 14 mg in Adults with Type 2 Diabetes (PIONEER PLUS). The Lancet, 2023. 
• Novo Nordisk - Annual Report 2025. 
• Novo Nordisk - FDA Approves Novo Nordisk's Oral Semaglutide for Cardiovascular Risk Reduction in Adults with Type 2 Diabetes, October 2025. 
• Novo Nordisk - FDA Approves Ozempic Tablets as the Proprietary Name for Oral Semaglutide, February 2026. 
• Novo Nordisk - Ozempic Pill Availability in the United States, May 2026. 
• Centers for Medicare & Medicaid Services (CMS) - Medicare GLP-1 Bridge, 2026. 
• Centers for Medicare & Medicaid Services - Information for Part D Plans: Medicare GLP-1 Bridge, 2026. 
• ClinicalTrials.gov - SOUL: Oral Semaglutide in Patients with Type 2 Diabetes and High Cardiovascular Risk.